Basic Information

Gene symbol CTAG1B Synonyms CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 Type of gene protein-coding
Description cancer/testis antigen 1B

GTO ID GTC0111
Trial ID NCT01343043
Disease Synovial Sarcoma
Altered gene NY-ESO-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment NY-ESO-1(c259)T Cells
HLAHLA-A*02:01
PhasePhase1
Recruitment statusCompleted
TitleA Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259 T in HLA-A2+ Patients With Synovial Sarcoma
Year2011
CountryUnited States
Company sponsorGlaxoSmithKline
Other ID(s)208466|ADP 04511|2015-005594-21
Vector information
Vectorlentivirus
ConstructNY-ESO-1c259T cells
Transgene/Inserted geneCTAG1B
Regulatory elementEF1α promoter; a Woodchuck hepatitis virus post-translational regulatory element (WPRE)
Vector production methodVector was produced at the City of Hope (Duarte, CA) using transient transfection with four plasmids expressing the transfer vector, rev, VSV-G, and gag/pol, in 293T cells. Supernatant was collected at multiple time points, clarified, treated with Benzonase, and concentrated by tangential flow filtration and centrifugation.

Clinical Result

Cohort 1
Administration route infusion
Dosage 0.125~5E9 cells
Donor type autologous
Pts 29
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1/25(CR); 9/25(PR); 2/25(PD); 12/25(SD); 1/25(NE)
Adverse reactions 25/29(All-cause mortality); 16/29(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders; Vascular disorders)
References PMID: 29891538 | 31651363

Relationship Graph

Overview of Knowledge Graph